Ticker brief
RHHBY ROCHE HOLDINGS LTD-SPONS ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$61.17
1 day
+2.6%
14 days
+13.1%
mkt cap
·
signals 14d
32
authors 14d
11
crowd 14d
+1.0σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-16 · now +0.35 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 10 | +0.18 |
| @OzmosiHealth | C | · | 8 | +0.50 |
| @fwpharma | B | -1.91 | 4 | +0.35 |
| @CrweWorld | C | · | 3 | +0.27 |
| @ResearchPulse1 | B | +1.26 | 1 | -0.10 |
| @harry03994688 | A | -0.16 | 1 | +0.50 |
| @KontraInvest | A | +1.21 | 1 | +0.10 |
| @FierceBiotech | A | -0.83 | 1 | -0.20 |
| @robertojirusta | C | -0.38 | 1 | +0.50 |
| @ElliottWaveSage | C | +0.28 | 1 | +0.50 |
| @BioStocks | C | -1.77 | 1 | +0.25 |
Recent signals30of 32 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BiopharmIQ | +0.00 | The author explains why FDA approval odds and estimated stock-move size should be evaluated together. | +7.1% | tweet ↗ |
| 2026-10-16 | @BiopharmIQ | +0.10 | The post compares an earlier FDA probability and move forecast with today's approval and 0.58% gain. | +7.1% | tweet ↗ |
| 2026-10-16 | @BiopharmIQ | +0.00 | The author explains why FDA approval odds and estimated stock-move size should be evaluated together. | +7.1% | tweet ↗ |
| 2026-10-16 | @BiopharmIQ | +0.50 | The FDA approved Enspryng as the first at-home subcutaneous treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | @BiopharmIQ | +0.50 | Enspryng received FDA approval for thyroid eye disease, with another decision expected in January 2027. | +7.1% | tweet ↗ |
| 2026-10-16 | @BiopharmIQ | +0.20 | The post summarizes opening biotech moves and their company-specific catalysts. | +7.1% | tweet ↗ |
| 2026-10-16 | @OzmosiHealth | +0.50 | FDA approved Roche's Enspryng as an at-home treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | @OzmosiHealth | +0.50 | FDA approved Roche's Enspryng as an at-home treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | @OzmosiHealth | +0.50 | FDA approved Genentech's Enspryng as an at-home treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | @OzmosiHealth | +0.50 | FDA approved Genentech's Enspryng as an at-home treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | @fwpharma | +0.50 | FDA cleared Roche's Enspryng as the first at-home thyroid eye disease therapy. | +7.1% | tweet ↗ |
| 2026-10-13 | @fwpharma | +0.30 | Roche added Rona's RNAi therapy to its metabolic pipeline through a $1.1B deal. | +13.8% | tweet ↗ |
| 2026-10-13 | @CrweWorld | +0.25 | Rona Therapeutics signs a global RNAi therapy license agreement with Roche | +13.8% | tweet ↗ |
| 2026-10-13 | @BioStocks | +0.25 | Roche signed an obesity-drug licensing deal with Rona Therapeutics worth up to $1.16B. | +13.8% | tweet ↗ |
| 2026-10-12 | @BiopharmIQ | +0.00 | Lists explicit October FDA decision dates for three drug candidates. | +13.1% | tweet ↗ |
| 2026-10-12 | @BiopharmIQ | +0.50 | FDA approved Tecentriq combination therapy for stage III dMMR colon cancer. | +13.1% | tweet ↗ |
| 2026-10-10 | @ElliottWaveSage | +0.50 | FDA accepted Genentech's vamikibart filing, with a decision due by July 2027. | +13.1% | tweet ↗ |
| 2026-10-10 | @BiopharmIQ | +0.00 | Weekly biotech roundup summarizes mixed clinical, commercial, and pipeline developments. | +13.1% | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.50 | FDA approved Roche's Tecentriq combination for adjuvant treatment of stage III colon cancer. | +13.1% | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.50 | FDA approved Genentech's Tecentriq combination for adjuvant stage III colon-cancer treatment. | +13.1% | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.50 | FDA approved Roche's Tecentriq combination for adjuvant treatment of stage III colon cancer. | +13.1% | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.50 | FDA approved Genentech's Tecentriq combination for adjuvant stage III colon-cancer treatment. | +13.1% | tweet ↗ |
| 2026-10-09 | @CrweWorld | +0.50 | FDA approved Roche's Tecentriq combination for adjuvant stage III colon-cancer treatment. | +13.1% | tweet ↗ |
| 2026-10-09 | @robertojirusta | +0.50 | The FDA cleared Roche's Tecentriq for colon cancer. | +13.1% | tweet ↗ |
| 2026-10-09 | @fwpharma | +0.50 | FDA cleared Roche's Tecentriq for dMMR colon cancer | +13.1% | tweet ↗ |
| 2026-10-08 | @FierceBiotech | -0.20 | Blood-sugar data weakened enthusiasm for Zealand and Roche's amylin obesity drug. | +14.6% | tweet ↗ |
| 2026-10-08 | @KontraInvest | +0.10 | Zealand and Roche announce mixed Phase 2 obesity and diabetes trial results. | +14.6% | tweet ↗ |
| 2026-10-08 | @harry03994688 | +0.50 | Argues Roche's AI-enabled R&D gains can improve biotech economics and valuations. | +14.6% | tweet ↗ |
| 2026-10-07 | @ResearchPulse1 | -0.10 | Reports that Roche paid $190M upfront for a Phase 1 UCN2 asset amid expanding obesity-drug interest. | +13.1% | tweet ↗ |
| 2026-10-07 | @CrweWorld | +0.05 | Reports Roche's delivery of laboratory equipment supporting Ebola testing in the DRC. | +13.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.